A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection


Due to the scarcity of data on prognostic and predictive influence on CCA, epidemiological studies evaluating these factors need to be developed in patients with CCA. Therefore, the investigators want to evaluate the profile of patients in the real world and from various parts of the world, describing prognostic factors such as CD4 dosage, time of HIV infection, evaluation of viral load, diagnosis of AIDS, geographic region of diagnosis and treatment, clinical staging, medications concomitant with QRT (risk of drug interactions), comorbidities (possible impact on dose-intensity), use of HAART, time of use of HAART, radiotherapy modality (conventional 3D vs Modulated Beam Intensity [IMRT], response to Nigro vs CTII regimens, as well as comparing clinical outcomes with patients without HIV infection.

Full Title of Study: “ACTION HIV (Anal Cancer TherapIes and Outcomes iNitiative for Patients Living With and Without HIV): A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: October 30, 2024

Arms, Groups and Cohorts

  • With HIV Infection
    • Patients with CCA with HIV infection,
  • Without HIV Infection
    • Patients with CCA without HIV infection,

Clinical Trial Outcome Measures

Primary Measures

  • Median disease-free survival
    • Time Frame: 3 years
    • Defined as time from Day 1 from initiation of treatment (or definition of exclusive supportive care) to tumor death or recurrence. Disease-free survival at 3 years after initiation of treatment: proportion of patients free of local or metastatic disease at 3 years after treatment termination according to imaging tests (chest, abdomen and pelvis scans) and clinical examination of anal inspection
  • Complete clinical response
    • Time Frame: 6 months
    • Absence of neoplasia on magnetic resonance imaging (preferred) or computed tomography of the pelvis and on clinical examination of anal inspection 6 months after the end of QRT or RT isolated
  • Overall survival
    • Time Frame: From first date of treatment to date of death from any cause, assessed up to 3 years.
    • Defined as the date from the D1 of treatment (or exclusive supportive care) to death from any cause; living patients at the time of the analysis will be censored.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients 18 years of age or older – Confirmed histological diagnosis of anal canal squamous cell carcinoma. Basaloid subtype is accepted – Have underundered serological test for HIV infection – Any clinical stage Exclusion Criteria:

  • Lack of data on treatments and clinical outcomes

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Latin American Cooperative Oncology Group
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.